Glucuronidation of anticancer prodrug PR-104A: Species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 3, 2011, Pages 692-702

  Gu, Yongchuan ^a   Tingle, Malcolm D ^b   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 BROMOETHYL)2 [[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANESULFONATE; 2 [(2 BROMOETHYL)2 [[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANESULFONATE 5 HYDROXYLAMINE; 2 [(2 BROMOETHYL)2 [[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANESULFONATE O GLUCURONIDE; 2 [(2 BROMOETHYL)2 [[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANESULFONATE PHOSPHATE ESTER; ALDOKETOREDUCTASE 1C3; ANTINEOPLASTIC AGENT; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 2B7; MESSENGER RNA; OXIDOREDUCTASE; PR 104; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONIC ACID;

ADULT; AGED; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME SPECIFICITY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; REDUCTION; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; DOGS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MICE; MICROSOMES, LIVER; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 79956220572     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180703     Document Type: Article

References (43)

1. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45. (Pubitemid 46043890)
2. Birtwistle J, Hayden RE, Khanim FL, Green RM, Pearce C, Davies NJ, Wake N, Schrewe H, Ride JP, Chipman JK, et al. (2009) The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res 662:67-74.
3. Brown JM and Wilson WR (2004) Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 4:437-447. (Pubitemid 38745529)
4. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al. (2002) Gene expression patterns in human liver cancers. Mol Biol Cell 13:1929-1939. (Pubitemid 34651483)
5. Connors TA and Whisson ME (1966) Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 210:866-867.
6. Court MH (2004) In vitro identification of UDP-glucuronosyl-transferases (UGTs) involved in drug metabolism, in Optimization in Drug Discovery: In Vitro Methods (Yan Z and Caldwell GW eds) pp 185-202, Humana Press Inc., Totowa, NJ.
7. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
8. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133. (Pubitemid 37048284)
9. Cullinan SB and Diehl JA (2006) Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 38:317-332. (Pubitemid 41821881)
10. Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, Smyth JF, and Jodrell DI (2003) Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res 63:8443-8450. (Pubitemid 37553155)
11. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
12. de Almagro MC, Selga E, Thibaut R, Porte C, Noé V, and Ciudad CJ (2011) UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochem Pharmacol 81:60-70.
13. Gu Y, Atwell GJ, and Wilson WR (2010) Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs and humans. Drug Metab Dispos 38:498-508.
14. Gu Y, Guise CP, Patel K, Abbattista MR, Lie J, Sun X, Atwell GJ, Boyd M, Patterson AV, and Wilson WR (2011) Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. Cancer Chemother Pharmacol 67:543-555.
15. Gu Y, Patterson AV, Atwell GJ, Chernikova SB, Brown JM, Thompson LH, and Wilson WR (2009) Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 8:1714-1723.
16. Gu Y and Wilson WR (2009) Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 877:3181-3186.
17. Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, et al. (2010) The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res 70:1573-1584.
18. Guise CP, Wang AT, Theil A, Bridewell DJ, Wilson WR, and Patterson AV (2007) Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74:810-820. (Pubitemid 47212075)
19. Helsby NA, Goldthorpe MA, Tang MH, Atwell GJ, Smith EM, Wilson WR, and Tingle MD (2008) Influence of mustard group structure on pathways of in vitro metabolism of anticancer N- (2-hydroxyethyl)-3,5-dinitrobenzamide-2-mustard prodrugs. Drug Metab Dispos 36:353-360. (Pubitemid 351185748)
20. Hill RP, Marie-Egyptienne DT, and Hedley DW (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19:106-111.
21. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171. (Pubitemid 27191615)
22. Jameson MB, McKeage MJ, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, and Tchekmedyian NS (2010a) Final results of a phase Ib trial of PR104, a preprodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors (Abstract). J Clin Oncol 28:2554.
23. Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, and Wilson WR (2010b) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65:791-801.
24. Juan TY, Roffler SR, Hou HS, Huang SM, Chen KC, Leu YL, Prijovich ZM, Yu CP, Wu CC, Sun GH, et al. (2009) Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity. Clin Cancer Res 15:4600-4611.
25. Knights KM and Miners JO (2010) Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev 42:63-73.
26. Konopleva M, Benito J, Shi Y-X, Konoplev S, Kornblau SM, Frolova O, Zweidler-McKay PA, Qiu Y, Wilson WR, Campana D, et al. (2009) Therapeutic targeting of the hypoxic microenvironment in acute lymphocytic leukemia (Abstract). Blood 114:2040.
27. Melink TJ, Jameson MB, McKeage MJ, and Gutheil JC (2008) A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug administered on a weekly schedule in patients with solid tumors (Abstract). J Clin Oncol 26:14543.
28. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
29. Nakamura A, Nakajima M, Higashi E, Yamanaka H, and Yokoi T (2008) Genetic polymorphisms in the 5′-flanking region of human UDP- glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet Genomics 18:709-720.
30. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
31. Patel K, Choy SF, Hicks KO, Melink TJ, Holford NHG, and Wilson WR (2010) A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol doi: 10.1007/s00280-010-1412-z.
32. Patel K, Lewiston D, Gu Y, Hicks KO, and Wilson WR (2007) Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 856:302-311. (Pubitemid 47302931)
33. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, et al. (2007) Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 13:3922-3932. (Pubitemid 47037600)
34. Prijovich ZM, Chen KC, and Roffler SR (2009) Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy. Mol Cancer Ther 8:940-946.
35. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, et al. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98:15149-15154. (Pubitemid 34013984)
36. Ritter JK (2000) Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171-193.
37. Roberts MS and Rowland M (1986) Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38:177-181. (Pubitemid 16162503)
38. Sawyer MB, Damaraju S, Pituskin E, Damaraju V, Scarfe AG, Bies RB, Hanson J, Clemons M, Kuzma M, and Mackey JR (2009) Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression (Abstract). J Clin Oncol 27:2504.
39. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, et al. (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61:7388-7393. (Pubitemid 32995021)
40. Taguchi K, Shimada M, Fujii S, Sumi D, Pan X, Yamano S, Nishiyama T, Hiratsuka A, Yamamoto M, Cho AK, et al. (2008) Redox cycling of 9,10-phenanthraquinone to cause oxidative stress is terminated through its monoglucuronide conjugation in human pulmonary epithelial A549 cells. Free Rad Biol Med 44:1645-1655.
41. Tercel M, Wilson WR, Anderson RF, and Denny WA (1996) Hypoxia-selective anti-tumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 39:1084-1094. (Pubitemid 26082941)
42. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208. (Pubitemid 39410902)
43. Wouters BG and Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8:851-864.